Search

Galectin Therapeutics Inc

Chiusa

SettoreSettore sanitario

3.96 2.59

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.5300000000000002

Massimo

3.94

Metriche Chiave

By Trading Economics

Entrata

-4.1M

-9.1M

EPS

-0.14

Dipendenti

9

EBITDA

2.2M

-827K

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+198.91% upside

Dividendi

By Acuity

Utili prossimi

13 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

39M

354M

Apertura precedente

1.37

Chiusura precedente

3.96

Notizie sul Sentiment di mercato

By Acuity

50%

50%

150 / 340 Classifica in Healthcare

Galectin Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ago 2026, 23:01 UTC

Shares of Galectin Therapeutics Inc. are lower in after-market trading, with notable volatility and a decline since Monday's close.

21 ago 2026, 19:16 UTC

Galectin Therapeutics Inc shares are higher today, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

20 ago 2026, 20:06 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

18 ago 2026, 19:56 UTC

Galectin Therapeutics Inc. shares are higher today, advancing since Monday's close despite earlier pulling back from session lows. The stock remains above its 20-day moving average.

17 ago 2026, 19:56 UTC

Galectin Therapeutics Inc. shares are trading higher, recovering from an earlier low and positioned above the 20-day moving average. No specific news was identified.

14 ago 2026, 19:21 UTC

News

Galectin Therapeutics reports a net loss of $9.2 million for Q2, missing estimates, contributing to a decline in shares during the session.

13 ago 2026, 20:02 UTC

Galectin Therapeutics Inc shares are higher during Thursday's session, reflecting strong trading activity and unusually high market volume, despite lacking specific company news.

12 ago 2026, 19:42 UTC

Galectin Therapeutics Inc shares are rising Wednesday amid high trading volume, maintaining an upward trend since Tuesday's close despite pulling back from earlier session highs.

11 ago 2026, 19:56 UTC

Galectin Therapeutics Inc shares are lower today amid routine fluctuations and no specific news. The stock is near the lower end of its one-month trading range.

10 ago 2026, 20:02 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a significant decline since Friday amid high trading volume and cautious investor sentiment following a weak jobs report.

8 ago 2026, 00:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, reflecting strong buying activity. The stock has recovered from an early session low.

7 ago 2026, 23:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, recovering from earlier losses amid favorable broader market conditions and a declining unemployment rate.

6 ago 2026, 22:06 UTC

Galectin Therapeutics Inc shares are lower in after-market trading, continuing a trend below their 20-day moving average amid a significant decline since last month.

5 ago 2026, 23:02 UTC

Galectin Therapeutics Inc shares are higher in after-market trading, despite no specific news driving the movement. The stock showed significant volatility during the session.

4 ago 2026, 20:03 UTC

News

Galectin Therapeutics announced a $105.8 million debt-to-equity conversion but shares are lower today after an early peak. Trading volume is unusually high.

3 ago 2026, 19:46 UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

31 lug 2026, 21:51 UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

30 lug 2026, 20:10 UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

29 lug 2026, 18:58 UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

28 lug 2026, 17:46 UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

27 lug 2026, 16:32 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

24 lug 2026, 20:02 UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

22 lug 2026, 19:01 UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

21 lug 2026, 17:16 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

20 lug 2026, 20:06 UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Confronto tra pari

Modifica del prezzo

Galectin Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

198.91% in crescita

Previsioni per 12 mesi

Media 11 USD  198.91%

Alto 11 USD

Basso 11 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Galectin Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

150 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
help-icon Live chat